Farxiga (dapagliflozin) clinical uses
Pro Research Analysisby 
Searched over 200M research papers
Dapagliflozin (Farxiga) Clinical Uses: Type 2 Diabetes Management
Dapagliflozin (Farxiga) is primarily used to treat type 2 diabetes. It works by inhibiting the sodium-glucose co-transporter-2 (SGLT2) in the kidneys, which reduces glucose reabsorption and increases glucose excretion in urine, thereby lowering blood sugar levels. This mechanism is independent of insulin, making dapagliflozin effective as both monotherapy and as an add-on to other antihyperglycemic agents, including metformin, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, and insulin Plosker2014Vivian2015Dhillon2019+3 MORE. Clinical trials have shown that dapagliflozin consistently reduces glycosylated hemoglobin (HbA1c), fasting plasma glucose, and body weight, with effects maintained over long-term use Plosker2014Dhillon2019Davis2016+2 MORE. It is also associated with a low risk of hypoglycemia, except when combined with insulin or sulfonylureas Plosker2014Vivian2015Dhillon2019+1 MORE.
Dapagliflozin (Farxiga) for Heart Failure
Dapagliflozin has been approved for the treatment of heart failure with reduced ejection fraction (HFrEF), regardless of whether patients have type 2 diabetes Siddiqui2024Blair20219. Clinical studies, including the DAPA-HF trial, have shown that dapagliflozin significantly reduces the risk of cardiovascular death or hospitalization for heart failure when added to standard therapy Blair20219. These benefits are observed in patients with or without diabetes and are consistent across different background heart failure treatments . Dapagliflozin is now considered a valuable option for managing symptomatic HFrEF Siddiqui2024Blair20219.
Dapagliflozin (Farxiga) in Chronic Kidney Disease
Dapagliflozin has also gained approval for use in chronic kidney disease (CKD). It can slow the progression of renal disease and reduce the risk of renal failure and death from renal causes in patients with or without diabetes Siddiqui2024Tingen2020. However, it is not recommended for patients with end-stage chronic kidney disease or moderate to severe renal impairment Plosker2014Siddiqui2024.
Additional Benefits and Considerations
Dapagliflozin offers additional benefits such as modest weight loss, reduction in blood pressure, and improvements in metabolic parameters like triglycerides and HDL cholesterol Plosker2014Dhillon2019Dhar2025. It is generally well tolerated, but common side effects include genital mycotic infections, urinary tract infections, and, rarely, diabetic ketoacidosis and Fournier’s gangrene Plosker2014Vivian2015Siddiqui2024+3 MORE. There is also ongoing research regarding its long-term cardiovascular safety and potential cancer risks Vivian2015Maranghi2015.
Conclusion
Dapagliflozin (Farxiga) is a versatile medication with established roles in managing type 2 diabetes, heart failure with reduced ejection fraction, and chronic kidney disease. Its benefits extend beyond glycemic control to include cardiovascular and renal protection, weight loss, and blood pressure reduction. However, careful patient selection and monitoring are important to minimize adverse effects and maximize therapeutic outcomes Plosker2014Vivian2015Siddiqui2024+7 MORE.
Sources and full results
Most relevant research papers on this topic
Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Dapagliflozin, an SGLT2 inhibitor, improves glycemic control in adults with type 2 diabetes by inhibiting renal reabsorption of glucose, offering a novel treatment option independent of insulin secretion or action.
DOI